Reviewer's report

Title: FemZone Trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients

Version: 2 Date: 20 May 2013

Reviewer: Adam M Brufsky

Reviewer's report:

This is a well written report which tends to corroborate previous information concerning a potential anti-tumor effect of zoledronic acid in breast cancer. While the finding do not meet statistical significance, the trend is interesting.

I would have liked to know the reasons for poor accrual, but the authors do hint at these reasons in their discussion. (Discretionary revision)

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests: Competing interests: none. I have no competing interests.